Perspectum announced that it has signed a strategic business partnership with Marubeni Corporation ("Marubeni") to support entry of Perspectum's AI diagnostic technology, called LiverMultiScan, into
Coronavirus impact: Seafood exports to China takes a major hit
SECTIONS
Share
Synopsis
Non-payments, as also delayed payments, by many importers in China and allegedly unreasonable post-shipment, transhipment and vessel waiting charges by shipping lines have become a regular feature, with no intervention from India’s trade authorities, said exporters.
Agencies
Exporters also said that freight rates have been progressively increased for reefer containers to the US to about $6,500 from $3,500 in March 2020.
Marine exports from India, mainly from the west coast of the country, have taken a hit as Chinese buyers fear the presence of Covid-19 in the packing material. China accounts for nearly 25% of India s marine exports. Seafood exporters said they are facing the brunt of non-payments and delayed payments by many Chinese importers.
Perspectum Appoints Annalisa Jenkins, MBBS, FRCP to Board of Directors
Perspectum, a commercial-stage, precision-health company developing proprietary digital technologies that enable clinicians to more accurately diagnose and monitor patients with chronic metabolic diseases, multi-organ pathologies and cancer, announced the appointment of Annalisa Jenkins, MBBS, FRCP to its Board of Directors.
Dr. Jenkins brings extensive expertise in advancing biopharma programs from discovery to regulatory approval, which she gained during a distinguished industry career, including roles as the former head of Global R&D for Merck Serono and Head of Global Medical Affairs for Bristol Myers Squibb. Over her 20-year career, she has served as a chairwoman or director on the board of 14 public and private companies, including Oncimmune, a company focused on the diagnosis and treatment of cancer. Dr. Jenkins is the current chair of the court at the London School of Hygiene and Tropical Medicine, a co
The Pharma Fast 50
PharmaTimes presents Alantra’s annual ranking of the fastest growing private pharma companies in the UK
In 2020 the world turned upside-down and the pharma sector was no exception. As COVID-19 spread globally and lockdowns took effect, the industry responded with a surge of adaptability, resilience and innovation.
This response is borne from the key trait we see every year in the constituents of the Alantra Pharma Fast 50, our annual ranking of the 50 fastest-growing privately owned pharmaceutical businesses in the UK. The common theme among these businesses is a relentless focus on innovation.
There has never been more public attention on what it takes to deliver an effective drug to patients than over the last 12 months. The businesses in the Pharma Fast 50 touch on every element of that – from early stage research right through to ensuring vital medicines continue to flow across borders. Some are using artificial intelligence (AI) to identify and design
100 days of long Covid torture and counting dailymail.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailymail.co.uk Daily Mail and Mail on Sunday newspapers.